Payment overview · 2025
General Payments
$69.64
4 reported records · 4 companies
Healthcare provider profile · identity verified
Daniel Jay Leisinger, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · WATERLOO, IA · NPI 1245506864
Verified facts
What the public records show
CMS Open Payments records show Daniel Jay Leisinger, D.O. received $69.64 in general payments during 2025 across 4 reported records.
VERTEX PHARMACEUTICALS INCORPORATED accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $19.20 | 27.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.26 | 26.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.86 | 24.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.32 | 22.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $69.64 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 369 | 82 |
| Lisinopril | Lisinopril | 351 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 277 | 41 |
| Gabapentin | Gabapentin | 224 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 213 | 46 |
| Potassium Chloride | Potassium Chloride | 192 | 33 |
| Omeprazole | Omeprazole | 179 | 35 |
| Furosemide | Furosemide | 168 | 40 |
| Metformin Hcl | Metformin Hcl | 163 | 33 |
| Losartan Potassium | Losartan Potassium | 145 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 28 |
| Eliquis | Apixaban | 130 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 27 |
| Trazodone Hcl | Trazodone Hcl | 125 | 24 |
| Simvastatin | Simvastatin | 122 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 23 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 89 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 16 |
| Sertraline Hcl | Sertraline Hcl | 84 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 21 |
| Trulicity | Dulaglutide | 83 | 11 |
| Meloxicam | Meloxicam | 80 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 14 |
| Famotidine | Famotidine | 76 | 16 |
| Buspirone Hcl | Buspirone Hcl | 72 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 19 |
| Morphine Sulfate | Morphine Sulfate | 66 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 14 |
| Spironolactone | Spironolactone | 58 | suppressed |
| Mirtazapine | Mirtazapine | 57 | suppressed |
| Scopolamine | Scopolamine | 57 | suppressed |
| Glipizide | Glipizide | 55 | 14 |
| Atenolol | Atenolol | 54 | 12 |
| Atropine Sulfate | Atropine Sulfate | 54 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 52 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 50 | 13 |
| Levocarnitine | Levocarnitine (With Sugar) | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Allopurinol | Allopurinol | 41 | suppressed |
| Carvedilol | Carvedilol | 41 | suppressed |
| Lorazepam | Lorazepam | 38 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Budesonide | Budesonide | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Erythromycin Ethylsuccinate | Erythromycin Ethylsuccinate | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 28 | 16 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 25 | 25 |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 20 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 20 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 19 | 19 |
| Alprazolam | Alprazolam | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 14 |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Acetylcysteine | Acetylcysteine | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Flunisolide | Flunisolide | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Perphenazine | Perphenazine | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Celecoxib | Celecoxib | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $69.64 · 4 records | VERTEX PHARMACEUTICALS INCORPORATED | Dexcom G6 Transmitter, JOURNAVX, Ozempic, Rybelsus, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error